A transaction theme involving the en bloc transfer of marketing authorizations, marketing rights and related rights for 13 long-listed products to 太陽ファルマ, followed by the transfer of rights and authorizations for pharmaceutical businesses, including the Bonviva Japan business. It concerns the streamlining of the business portfolio through the transfer of pharmaceutical marketing authorizations and sales rights.